547 related articles for article (PubMed ID: 16810332)
1. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
2. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
4. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
5. Inducing synthetic lethality using PARP inhibitors.
Boss DS; Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
[TBL] [Abstract][Full Text] [Related]
6. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Davies H; Glodzik D; Morganella S; Yates LR; Staaf J; Zou X; Ramakrishna M; Martin S; Boyault S; Sieuwerts AM; Simpson PT; King TA; Raine K; Eyfjord JE; Kong G; Borg Å; Birney E; Stunnenberg HG; van de Vijver MJ; Børresen-Dale AL; Martens JW; Span PN; Lakhani SR; Vincent-Salomon A; Sotiriou C; Tutt A; Thompson AM; Van Laere S; Richardson AL; Viari A; Campbell PJ; Stratton MR; Nik-Zainal S
Nat Med; 2017 Apr; 23(4):517-525. PubMed ID: 28288110
[TBL] [Abstract][Full Text] [Related]
7. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
[TBL] [Abstract][Full Text] [Related]
8. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
9. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
11. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
McCabe N; Lord CJ; Tutt AN; Martin NM; Smith GC; Ashworth A
Cancer Biol Ther; 2005 Sep; 4(9):934-6. PubMed ID: 16251802
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Hay T; Matthews JR; Pietzka L; Lau A; Cranston A; Nygren AO; Douglas-Jones A; Smith GC; Martin NM; O'Connor M; Clarke AR
Cancer Res; 2009 May; 69(9):3850-5. PubMed ID: 19383921
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
17. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
18. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]